A blog exploring pharmaceutical relationship marketing, emarketing and innovation with a focus on rare disorders.
SirenWired
The convergence of rare disease, digital communications, and pharmaceutical marketing communications

#SocPharm Tweetchat Transcript 2/1/2012

Posted by | 11:33pm on Wednesday, February 1, 2012

:
Welcome to the #socpharm tweetchat. For the next hour we’ll be talking biopharma marketing & sm. Say hello!

:
Hello, #socpharm – Dana Webster from Avant Healthcare Mktg (opinions are my own)

:
Hola @: : Welcome to the #socpharm tweetchat. For the next hour we’ll be talking biopharma marketing & sm. Say hello!

:
We’ll assume your tweets reflect your own opinion, not your employers or clients. They are not legal or health advice! #socpharm

:
Hi #socpharm ers!

:
Do we want to talk google privacy first or FDA labeling guidance? #socpharm

:
I’m game for either topic #socpharm

:
@: hello #socpharm

:
T1: Does Google’s new privacy policy: http://t.co/S9djLelE take them closer to being Big Brother? #socpharm

:
Welcome back friend! RT @: hello #socpharm

:
T1: If you don’t like Google’s terms you are always free to choose to use other services. #socpharm

:
The latter RT @: Do we want to talk google privacy first or FDA labeling guidance? #socpharm

:
@: Welcome! We’ll get to FDA in a few minutes, sorry we already started on google! #socpharm

:
Agree with @: – I do not feel my privacy is compromised and accept their terms (disclosure: Android user) #socpharm

:
Clarification: agree that I have the option to go elsewhere #socpharm

:
@ agreed “If you don’t like Google’s terms you are always free to choose to use other services.” #socpharm

:
@: they have so many services, it will increasingly be diff to keep track of how personal & behavioral data being used #socpharm

:
@: they have so many services, it will increasingly be diff to keep track of how personal & behavioral data being used #socpharm

:
Yes but Google/Android everywhere MT @: T1: If you don’t like Google you are always free to choose to use others. #socpharm

:
No comments on Google? Do people generally feel decreased privacy is price we are willing to pay for free services? #socpharm

:
@ Sorry big time delay! #socpharm

:
Janet from Chicago joining late. Healthcare call center background including patient adherence and clinical trials. #socpharm

:
T1: No decreased privacy is the price we pay for using the easy default #socpharm

:
T1: More concerning to me was high inclusion of Google+ streams in organic search results http://t.co/mhVGRZRZ #socpharm

:
T1: yet to find the benefit of Google+ other than influence on Google Analytics moving forward #socpharm

:
#socpharm T1 @: Agreed, I don’t think Google+ results should go on Google, at least not without an “opt out” feature like fb has

:
T2: FDA guidance on brand/generic names – mentions “computer-based” ads. Big change? http://t.co/EaRi7C7D #socpharm

:
Hi there! Frieda Hernandez joining #socpharm late, will have to catch up.

:
@: T1: i too find it concerning bec means search results may become skewed, #socpharm

:
T2: Per FDA even w/header, logo, ect using generic has to b in “running” text too. Review of most big brand sites, not the case #socpharm

:
@: T2: seems 2be going against consumer friendly language-complicated generic names r not easy or 5th gr reading level #socpharm

:
BTW, does everyone know every time someone mentions FDA during #socpharm chat we have to sip our drink? Mine is water tonight :)

:
#socpharm T2: also a lot of ambiguity there. Would be nice if guidance was more clear-cut

:
@: Agree. Use of the word “screen” is confusing. Screen size of iphone, ipad, laptop & monitor r all vastly different #socpharm

:
#socpharm T2: but that’s nothing new for the #FDA… like @: ‘s “drinking” game lol

:
@: Mine is water, too….still lots of work to to this evening #socpharm

:
#FDA and clear-cut are rarely used in the same sentence. I think lawyers have something to do with that :) #socpharm

:
RT @: : #FDA and clear-cut are rarely used in the same sentence. I think lawyers have something to do with that :) #socpharm

:
Agreed. RT @: : T1: yet to find the benefit of Google+ other than influence on Google Analytics moving forward #socpharm

:
Has everyone said all they have to about latest FDA guidelines? Think I’ll create a generic name for myself :) #socpharm

:
And mobile aps different as well MT @: @: Agree. Screen size of iphone, ipad, laptop & monitor r not the same #socpharm

:
LOL! Maybe crowdsource it re: create a generic name for myself @: #socpharm

:
Speaking of mobile. T3: Brands Continue Limited Mobile Site Offerings http://t.co/zSrt0ngr Why do you think that is? #socpharm

:
No I’d be afraid of result! RT @: : LOL! Maybe crowdsource it re: create a generic name for myself @: #socpharm

:
Drug companies spent $516 million lobbying in 3009/2010 #hcsm #socpharm #mHealth #epharma #hcmktg #fdasm #pharmamktg

:
T3: Mobile versions of websites always stripped down versions of desktop. Not sure if because small screen or lack of power #socpharm

:
T3: For some clients it comes down to prioritizing resources & mobile sites haven’t made it to top of list yet. Getting there. #socpharm

:
#socpharm T3: agree with @: but I think this should be a priority, even over ::gasp:: social media. mobile=more pervasive

:
T3: Problem with #pharma and mobile sites is how would you display fair balance info? (not a programmer nor play one on TV). #socpharm

:
T3: My fav stat, ironically frm Google, is 24% of all prescription searches in 2011 are estimated to come from mobile devices. #socpharm

:
T3: as a pt, I am interested in apps that manage my disease but not so much product specific #socpharm

:
@: True, mobile ppc or sites aren’t as sexy as FB or Google+! Probably more effective but not as hott!! #socpharm

:
@ LOL. Yes, the talented geeks can work that out. #socpharm

:
RT @: : T3: My fav stat, ironically frm Google, 24% of all Rx searches in 2011 are est. to come from mobile devices. #socpharm

:
gd insight. RT @: : T3: as a pt, i’m interested in apps that manage my disease but not so much product specific #socpharm #epatient

:
Any final thoughts in last few minutes? Anyone read any good books or articles they’d like to share? Or speaking gigs? #socpharm

:
Next week @ will be guest moderating and then on Feb 15 will be @: . Hope to see you all then. #socpharm

:
Speaking of mobile RT @: Takeaways From BDI’s Mobile Healthcare Comms Conference http://t.co/0LSSEXll #socpharm

:
@ You are a busy man. Do you have a list of all your speaking engagements? #socpharm

:
Thanks for a great chat #socpharm ers see you next week!

:
Tx for sharing MT @: Speaking of mobile RT @: Takeaways From BDI’s Mobile HC Comms Conf fhttp://bit.ly/xFESet #socpharm

:
Have a great night & thanks everyone for joining in. I’ll post the transcript tomorrow. #socpharm

:
@ to speak at the Economist #pharmasummit in London on 2/9, “Putting Patients at the Centre” #socpharm #raredisease #patient #s4pm

:
@ Sorry I couldnt get on today. Am still at work, but I hate missing #socpharm

:
Nite all and thanks! MT @: Have a great night & thanks everyone for joining in. I’ll post the transcript tomorrow. #socpharm

:
Good nite #socpharm peeps! Another great chat thanks to @: and all who participated.

:
@ I hear you, Darshan! I’m still at work too. We missed you on #socpharm, now back to the salt mines :-)

About Eileen O'Brien

Eileen has more than 16 years of digital healthcare marketing experience. She is an opinion leader on social media and biopharma, and has been invited to speak at industry conferences and quoted in publications.

View other posts from Eileen

5 Pingbacks/Trackbacks

    02 February 2012 at 5:02pm
    Transcript from last night's ...
  • Eileen O'Brien
  • 02 February 2012 at 6:02pm
    RT @eileenobrien: Transcript from ...
  • Christiane Truelove
  • 02 February 2012 at 6:02pm
    RT @eileenobrien: Transcript from ...
  • Chris Iafolla
  • 02 February 2012 at 7:02pm
    Excited about guest moderating this ...
  • Marc Monseau
  • 05 February 2012 at 3:02pm
    topic idea:thoughts on J&J Texas ...
  • soulful sepulcher
Siren Interactive
  • Siren Interactive
  • Rare Disease Relationship Marketing Experts
  • 626 West Jackson Blvd, Suite 100
  • Chicago, IL 60661
  • 312.204.6700
  • 866.502.6714 (Toll Free)
  • www.sireninteractive.com